Appropriateness Criteria for Active Surveillance of Prostate Cancer

Journal of Urology

Volumn 197, Issue 1, 2017, Pages 67-74

  Cher, Michael L ^a   Dhir, Apoorv ^b   Auffenberg, Gregory B ^b   Linsell, Susan ^b   Gao, Yuqing ^b   Rosenberg, Bradley ^d   Jafri, S Mohammad ^d   Klotz, Laurence ^f   Miller, David C ^b   Ghani, Khurshid R ^b   Bernstein, Steven J ^b,c   Montie, James E ^b   Lane, Brian R ^e  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^d Comprehensive Urology ^*  (United States)

^e SPECTRUM HEALTH   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

counseling; decision making; program evaluation; prostatic neoplasms; watchful waiting

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER EPIDEMIOLOGY; CANCER PATIENT; GLEASON SCORE; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MICHIGAN; PATIENT COUNSELING; PRIORITY JOURNAL; PROGRAM APPROPRIATENESS; PROSTATE BIOPSY; PROSTATE CANCER; TUMOR VOLUME; UROLOGIST; AGE; AGED; BLOOD; CANCER GRADING; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MORTALITY; NEEDLE BIOPSY; ORGANIZATION AND MANAGEMENT; PATHOLOGY; PROGNOSIS; PROGRAM EVALUATION; PROSTATE TUMOR; REGISTER; RISK ASSESSMENT; SURVIVAL ANALYSIS; TUMOR INVASION; UROLOGY; VERY ELDERLY; WATCHFUL WAITING;

AGE FACTORS; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; PROGNOSIS; PROGRAM EVALUATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGISTRIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; UROLOGY; WATCHFUL WAITING;

EID: 85003422216     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2016.07.005     Document Type: Article

References (11)

1. 1 Cooperberg, M.R., Carroll, P.R., Trends in management for patients with localized prostate cancer, 1990-2013. JAMA, 314, 2015, 80.
2. 2 Womble, P.R., Montie, J.E., Ye, Z., et al. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer. Eur Urol, 67, 2015, 44.
3. 3 Filson, C.P., Schroeck, F.R., Ye, Z., et al. Variation in use of active surveillance among men undergoing expectant treatment for early stage prostate cancer. J Urol, 192, 2014, 75.
4. 4 Hoffman, K.E., Niu, J., Shen, Y., et al. Physician variation in management of low-risk prostate cancer: a population-based cohort study. JAMA Intern Med, 174, 2014, 1450.
5. 5 Fitch, K., Bernstein, S.J., Aguilar, M.D., et al. The RAND/UCLA Appropriateness Method User's Manual. 2001, RAND, Santa Monica pp xiii, 109.
6. 6 Lawson, E.H., Gibbons, M.M., Ko, C.Y., et al. The appropriateness method has acceptable reliability and validity for assessing overuse and underuse of surgical procedures. J Clin Epidemiol, 65, 2012, 1133.
7. 7 Welty, C.J., Cowan, J.E., Nguyen, H., et al. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer. J Urol, 193, 2015, 807.
8. 8 Silberstein, J.L., Feibus, A.H., Maddox, M.M., et al. Active surveillance of prostate cancer in African American men. Urology, 84, 2014, 1255.
9. 9 Sundi, D., Faisal, F.A., Trock, B.J., et al. Reclassification rates are higher among African American men than Caucasians on active surveillance. Urology, 85, 2015, 155.
10. 10 Becker, A., Seiler, D., Kwiatkowski, M., et al. A comparative assessment of active surveillance for localized prostate cancer in the community versus tertiary care referral center. World J Urol, 32, 2014, 891.
11. 11 Gaylis, F., Cohen, E., Calabrese, R., et al. Active surveillance of prostate cancer in a community practice: how to measure, manage, and improve?. Urology, 93, 2016, 60.